74 studies found for:    INFLAMMATORY BOWEL DISEASE 3
Show Display Options
Rank Status Study
1 Completed A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.
Conditions: Crohn's Disease;   Inflammatory Bowel Disease
Intervention: Drug: Probiotic - VSL#3
2 Recruiting The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease
Conditions: Crohn Disease;   Ulcerative Colitis
Intervention: Dietary Supplement: VSL#3
3 Completed Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
Conditions: Crohn's Disease (CD);   Ulcerative Colitis (UC)
Intervention: Dietary Supplement: Vitamin D3
4 Completed Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
Conditions: Inflammatory Bowel Disease;   Ulcerative Colitis
Intervention: Drug: Balsalazide disodium
5 Recruiting Weekly Vitamin D in Pediatric IBD
Conditions: Inflammatory Bowel Diseases;   Skin Pigmentation
Intervention: Dietary Supplement: Vitamin D3 (cholecalciferol)
6 Enrolling by invitation A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Conditions: Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
Interventions: Drug: Placebo;   Drug: Ustekinumab
7 Active, not recruiting A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Conditions: Crohn's Disease;   Inflammatory Bowel Disease;   IBD;   Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo;   Drug: Group 2 ustekinumab 130 mg
8 Completed A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Conditions: Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
9 Recruiting The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Vitamin D;   Drug: Placebo
10 Active, not recruiting Oral OKT3 for the Treatment of Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Oral OKT3
11 Recruiting Gastrointestinal Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit
Condition: Ulcerative Colitis
Intervention: Device: Motilis-3D-transit
12 Recruiting Gastrointestinal Transit Times and Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit
Condition: Ulcerative Colitis
Intervention: Device: Motilis-3D transit
13 Recruiting A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: VSL#3
14 Completed Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
Condition: Crohn's Disease
Intervention: Drug: Infliximab
15 Completed Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Dietary Supplement: VSL#3;   Dietary Supplement: Placebo
16 Recruiting The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease
Condition: Crohn's Disease
Intervention: Dietary Supplement: VSL#3
17 Unknown  VSL#3 Treatment in Children With Crohn's Disease
Condition: Crohn's Disease
Interventions: Dietary Supplement: VSL#3®;   Dietary Supplement: Placebo
18 Completed VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: VSL#3;   Other: Placebo
19 Completed Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Condition: Crohn's Disease
Interventions: Drug: Semapimod;   Drug: Placebo
20 Completed An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Epanova™ (Omega-3 Free Fatty Acids)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years